We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. WE´RE NOT CURRENTLY HIRING
Switzerland
Joined July 2015
- Tweets229
- Following70
- Followers242
- Likes11
Exciting progress!
NLS Pharmaceutics & Aexon Labs expand the #DOXA platform with the #AEX6xx series — targeting cognition, arousal, & neuroprotection. A strong step toward next-gen #CNS innovation
finance.yahoo.com/news/nls-p…
The BIRD Foundation will continue supporting ITOL-102, our joint Diabetes program with @iToleranceBio — now part of NewCelX Ltd. @KadimastemLTD
#NLSPharma #BIRDFoundation #NewCelX #CellTherapy #diabeteschat
finance.yahoo.com/news/nls-p…
It’s official! ✅ @Nasdaq has approved our merger with @KadimastemLTD .
Closing expected Oct 30, 2025 — forming NewCelX (Nasdaq: NCEL), a global biotech innovator advancing cell & CNS therapies.
#NLSPharmaceutics #Kadimastem #NewCelX #Nasdaq #biotech
finance.yahoo.com/news/nls-k…
NLS shareholders approved the merger with @KadimastemLTD✅
Huge milestone cleared before forming NewCelX Ltd. (Nasdaq: NCEL) → a diversified biotech uniting cell therapy & CNS expertise.
finance.yahoo.com/news/nls-p…
Exciting news! 🎉 The @SECGov has declared effective our Form F-4 for the planned merger with @Kadimastem.
The combined company, NewCelX, will unite cell therapy & small-molecule innovation to tackle #ALS, #Diabetes, & #CNS disorders.
finance.yahoo.com/news/kadim…
🚨 Patent milestone: Our merger partner @KadimastemLTD secures IP protection in Hong Kong for its IsletRx #diabetes program—expanding global coverage after Europe, U.S. & India. Hong Kong = key Asia hub + gateway to China. finance.yahoo.com/news/nls-p…
Big news! BIRD Foundation greenlights more funding for iTOL-102, our merger partner's diabetes cure-in-progress with @KadimastemLTD & @iTolerance_inc . Plus: our CSO Dr. Eric Konofal is shortlisted for the 2025 Prix Galien for his groundbreaking work in narcolepsy! 🧠💉
We’ve closed the final $1M of our $3M financing! This supports our merger with Kadimastem and advances programs in ALS and diabetes. @KadimastemLTD #biotech #regenerativemedicine
finance.yahoo.com/news/nls-p…
CEO Issues Letter to shareholders: NLS has raised $6M+, cleared all debt, and advanced key clinical programs. The Kadimastem merger is on track as we prepare for ALS and diabetes trials.
🧾 finance.yahoo.com/news/nls-p…
#Biotech #ALS #Diabetes #CNS
At @ASCPorg NLS Pharmaceutics will present preclinical results showing Mazindol ER reduces both fentanyl reward and withdrawal symptoms in animal models.
A promising non-opioid approach to fighting addiction.
📍Poster #KO-943 | May 29
#CNS #PharmaNews #OpioidCrisis
ALT https://finance.yahoo.com/news/nls-pharmaceutics-present-data-dual-113000452.html?guccounter=1
Exciting news! NLS' KO-943 study shows Mazindol reduces fentanyl-induced reward in animal models! As we prepare for our merger with @KadimastemLTD, Mazindol remains a key focus for future strategic partnerships in addiction treatment. #AddictionResearch #addiction #biotech
ALT https://finance.yahoo.com/news/nls-pharmaceutics-announces-positive-results-130000361.html
NLS has announced the closing of up to $2M equity financing and a $25M equity facility agreement! These financial resources will support our merger with @KadimastemLTD and the advancement of clinical trials for transformative therapies in ALS and diabetes. Exciting times ahead!
ALT https://finance.yahoo.com/news/nls-pharmaceutics-kadimastem-announces-3-131000698.html
NLS Pharmaceutics announces new preclinical data for AEX-2, our groundbreaking dual orexin receptor agonist! 🧠✨ AEX-2 enhances wakefulness & reduces cataplexy—transforming sleep disorder treatments! #innovationquotes feeds.issuerdirect.com/news-…
👏 Kudos to @KadimastemLTD and @iTolerance_inc ! They completed a pre-IND meeting with the @US_FDA, bringing us closer to a potential cure for Type 1 Diabetes. Exciting times ahead for our future combined company!nasdaq.com/press-release/kad…
Big news from NLS Pharmaceutics! We raised $3.2M in a private placement and settled $4M in debt. Plus, we believe we’ve regained Nasdaq compliance!
Full article: rb.gy/8qqfjr
#nlspharmaceutics #narcolepsy $NLSP
NLS Pharmaceutics (Nasdaq: NLSP) announces 1-for-40 reverse share split effective Sept 27, 2024. Shares will trade under the same symbol “NLSP” but with a new CUSIP.
Full article: rb.gy/mgkk8e
#nlspharmaceutics #narcolepsy $NLSP
NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem (KDST.TA) are merging!
Kadimastem shareholders to hold 85%
New entity to trade on Nasdaq as Kadimastem
NLS’s DOXA platform continues
Read the full article here: rb.gy/wnw14a
#nlspharmaceutics $NLSP
